Business Context and Reporting Period
Company: Achieve Life Sciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 27, 2024
Principal Executive Offices: Bothell, WA and Vancouver, B.C., Canada
Trading Symbol: ACHV (NASDAQ)
Key Financial Metrics and Capital Structure
This filing does not report operational financial metrics such as revenue, profit, cash flow, margins, or existing debt levels. The document focuses exclusively on a new capital raising mechanism.
- Proposed Offering Size: Up to $50,000,000 in aggregate offering price.
- Instrument: Common Stock, par value $0.001 per share.
- Sales Agent: Jefferies LLC.
- Compensation: Up to 3.0% of gross proceeds.
Material Changes and Agreements
On September 27, 2024, the Company entered into an Open Market Sale Agreement (the "Sale Agreement") with Jefferies LLC to establish an "at-the-market" (ATM) offering program. Key terms include:
- Program Structure: The Company may sell shares from time to time at its sole discretion through Jefferies as sales agent.
- Registration Basis: Shares will be issued pursuant to a Registration Statement on Form S-3 filed on June 28, 2024.
- Flexibility: The Company has no obligation to sell any shares and may suspend the program at any time.
- Termination: The program terminates upon the sale of the maximum amount or earlier termination by either party.
Guidance, Outlook, and Use of Proceeds
Management intends to use the net proceeds from the ATM Program for the following purposes:
- Funding clinical development of cytisinicline.
- Funding other cytisinicline-related research and clinical development activities.
- Working capital and general corporate purposes.
Risks and Contingencies: The filing notes that the Company may suspend the program at any time. The description of the agreement is qualified by reference to the full text of the Sale Agreement filed as Exhibit 1.1.
Investor Verification Checklist
- Verify the current share price and potential dilution impact of selling up to $50 million in shares.
- Review the full text of the Open Market Sale Agreement (Exhibit 1.1) for specific conditions and termination rights.
- Confirm the status of the Form S-3 Registration Statement filed on June 28, 2024.
- Monitor future filings for actual sales volumes and proceeds generated under the ATM program.
- Assess the Company's current cash runway relative to the stated need for clinical development funding.